Bristol-Myers Squibb Oncology: Legacy and Leadership
Bristol-Myers Squibb provided its first anticancer medication for patients more than four decades ago – a medicine that’s still being prescribed today. Now, with an ongoing oncology portfolio of approved medicines and compounds in development, Bristol-Myers Squibb is poised with a reinvigorated franchise and a mandate for leadership.
Indeed, since 2004, the company has launched three new anticancer medications, acquired two biotech companies with leading-edge oncology programs, formed alliances with key scientific partners through its String of Pearls strategy of acquisitions, alliances and partnerships, and built a more robust pipeline of early and late-stage anticancer compounds.
Now, the company’s oncology R&D pipeline of about 20 compounds in development represents a wide range of proven and potential treatment platforms, including traditional cytotoxins as well as biologics, immunotherapies and other novel and targeted approaches. All told, the company is conducting about 200 oncology clinical trials, addressing 20 different tumor types.
Among the most exciting areas of research is immuno-oncology. Bristol-Myers Squibb’s work in the field of immuno-oncology began in the mid-1990s, and picked up momentum in 2005 when the company formed a collaborative alliance with Medarex Inc. Bristol-Myers Squibb acquired Medarex in August 2009 and assumed full rights to ipilimumab – an investigational compound in late-stage development for metastatic melanoma – and other early-stage investigational cancer compounds, positioning itself for long-term leadership in this area.
Another biotech acquisition has bolstered the company’s oncology pipeline and development expertise: Adnexus Therapeutics. This 2007 purchase brought the company discovery and early development capabilities for a new class of targeted protein-based drugs.
For its part, Bristol-Myers Squibb’s internal oncology discovery engine has produced two approved medications in 2006 and 2007, followed by a potentially first in class investigational compound currently in Phase III clinical development.
The hallmark of Bristol-Myers Squibb’s legacy of innovative cancer treatments – true 40 years ago as it is today – is the company’s commitment to patients.